Evidence map›Paper›PMID 31013780›Full record

ArticleInternational journal of molecular sciences2019

Anti-Apoptotic Effects of Recombinant Human Hepatocyte Growth Factor on Hepatocytes Were Associated with Intrahepatic Hemorrhage Suppression Indicated by the Preservation of Prothrombin Time.

Sotaro Motoi, Hiroko Toyoda, Takashi Obara, Etsuko Ohta, Yoshihisa Arita, Kana Negishi, Katsuhiro Moriya, Yoshikazu Kuboi, Motohiro Soejima, Toshio Imai and 3 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. HGF/c-Met: A Key Promoter in Liver Regeneration.Frontiers in pharmacology · 2022
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Sotaro MotoiEisai Co., Ltd., KAN Product Creation Unit, Eisai Product Creation Systems, 5-1-3 Tokodai, Tsukuba, Ibaraki 3002635, Japan. s-motoi@kan.eisai.co.jp.
Hiroko ToyodaEisai Co., Ltd., KAN Product Creation Unit, Eisai Product Creation Systems, 5-1-3 Tokodai, Tsukuba, Ibaraki 3002635, Japan. htoyoda1106@gmail.com.
Takashi ObaraEisai Co., Ltd., KAN Product Creation Unit, Eisai Product Creation Systems, 5-1-3 Tokodai, Tsukuba, Ibaraki 3002635, Japan. t-obara@hhc.eisai.co.jp.
Etsuko OhtaEisai Co., Ltd., KAN Product Creation Unit, Eisai Product Creation Systems, 5-1-3 Tokodai, Tsukuba, Ibaraki 3002635, Japan. e2-ota@hhc.eisai.co.jp.
Yoshihisa AritaKAN Research Institute, Inc., 6-8-2 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo 6500047, Japan. y-arita@kan.eisai.co.jp.
Kana NegishiKAN Research Institute, Inc., 6-8-2 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo 6500047, Japan. k-negishi@kan.eisai.co.jp.
Katsuhiro MoriyaEisai Co., Ltd., KAN Product Creation Unit, Eisai Product Creation Systems, 5-1-3 Tokodai, Tsukuba, Ibaraki 3002635, Japan. moriya@hhc.eisai.co.jp.
Yoshikazu KuboiEisai Co., Ltd., KAN Product Creation Unit, Eisai Product Creation Systems, 5-1-3 Tokodai, Tsukuba, Ibaraki 3002635, Japan. y-kuboi@kan.eisai.co.jp.
Motohiro SoejimaEisai Co., Ltd., KAN Product Creation Unit, Eisai Product Creation Systems, 5-1-3 Tokodai, Tsukuba, Ibaraki 3002635, Japan. m-soejima@kan.eisai.co.jp.
Toshio ImaiKAN Research Institute, Inc., 6-8-2 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo 6500047, Japan. t-imai@kan.eisai.co.jp.
Akio IdoDigestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan. ido-akio@m2.kufm.kagoshima-u.ac.jp.
Hirohito TsubouchiDepartment of Gastroenterology and Hepatology, Kagoshima City Hospital, 37-1 Uearata-cho, Kagoshima 8908760, Japan. tsubouchi-h62@kch.kagoshima.jp.
Tetsu KawanoKAN Research Institute, Inc., 6-8-2 Minatojima-Minamimachi, Chuo-Ku, Kobe, Hyogo 6500047, Japan. t-kawano@kan.eisai.co.jp.
Eisai (Japan) · JPKAN Research Institute · JPKagoshima City Hospital · JPKagoshima University · JP

Funding

Japan Agency for Medical Research and Development (AMED) 16im0110801h0006
6 · The paper itself

Abstract

Hepatocyte growth factor (HGF) is an endogenously expressed bioactive substance that has a strong anti-apoptotic effect. In this study, we biochemically and histologically characterized the effects of rh-HGF on in vitro human hepatocyte injury and mouse acute liver failure (ALF) models, both of which were induced by antibody-mediated Fas signaling. rh-HGF inhibited intracellular caspase-3/7 activation and cytokeratin 18 (CK-18) fragment release in both models. Histologically, rh-HGF dramatically suppressed parenchymal damage and intrahepatic hemorrhage. Among the laboratory parameters, prothrombin time (PT) was strongly preserved by rh-HGF, and PT was well correlated with the degree of intrahepatic hemorrhage. These results showed that the anti-apoptotic effect of rh-HGF on hepatocytes coincided strikingly with the suppression of intrahepatic hemorrhage. PT was considered to be the best parameter that correlated with the intrahepatic hemorrhages associated with hepatocellular damage. The action of rh-HGF might derive not only from its anti-apoptosis effects on liver parenchymal cells but also from its stabilization of structural and vasculature integrity.

Indexed as

AnimalsApoptosisBlood CoagulationCells, CulturedDisease Models, Animalfas ReceptorHemorrhageHepatocyte Growth FactorHepatocytesHumansInhibitory Concentration 50Liver DiseasesLiver Failure, AcuteMaleMiceProthrombin Timefas ReceptorHepatocyte Growth FactorHGF protein, humanRecombinant Proteinsacute liver failurecytokeratin-18Fas antigenhepatocyte growth factorprothrombin time

Identifiers

PMID31013780
PMCPMC6514566
OpenAlexW2937382566

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.